Thu, Jun 18, 2026
[Archive]
Volume 18, Issue 1 (March-2026 2026)
Iranian Journal of Blood and Cancer 2026, 18(1): 40-48 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Saeedi N, Khalili Tanha G, Judaki A A, Nazari E. Extracellular Immune Signatures as Prognostic Biomarkers and Liquid-Biopsy Candidates in AML. Iranian Journal of Blood and Cancer 2026; 18 (1) :40-48
URL: http://ijbc.ir/article-1-1831-en.html
URL: http://ijbc.ir/article-1-1831-en.html
1- Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran.
2- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. & Department of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. & Department of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (113 Views)
Background: Acute myeloid leukemia (AML) has poor long-term survival, necessitating robust prognostic biomarkers. While conventional markers focus on cytogenetics and mutations, immune-extracellular genes suitable for liquid biopsy remain understudied.
Methods: RNA-sequencing data from 200 AML patients were analyzed from The Cancer Genome Atlas (TCGA). Univariate Cox regression identified survival-associated genes. Gene Ontology enrichment analysis selected immune and extracellular genes, with Kaplan-Meier analysis validating prognostic significance. REACTOME pathway enrichment revealed biological mechanisms. External validation used GEPIA2.
Results: Cox regression identified 201 survival-associated genes (p<0.05): 149 favorable prognosis (HR<1) and 52 poor prognosis (HR>1). Gene Ontology enrichment revealed 29 immune-associated and 9 extracellular genes, with 5 overlapping candidates. Kaplan-Meier analysis confirmed four genes; EPHA10, CD160, BTN2A2, and KLRK1 as significant protective prognostic markers (p<0.05, HR<1). REACTOME analysis highlighted immune signaling pathways including adaptive immune response, natural killer cell-mediated cytotoxicity, and cell surface interactions. External validation demonstrated differential expression in AML versus normal tissues.
Conclusion: This study identified EPHA10, CD160, BTN2A2, and KLRK1 as novel immune-extracellular prognostic biomarkers in AML. These genes represent promising candidates for liquid biopsy applications and personalized immunotherapy strategies, offering new perspectives for monitoring immune surveillance and overcoming AML immune evasion.
Methods: RNA-sequencing data from 200 AML patients were analyzed from The Cancer Genome Atlas (TCGA). Univariate Cox regression identified survival-associated genes. Gene Ontology enrichment analysis selected immune and extracellular genes, with Kaplan-Meier analysis validating prognostic significance. REACTOME pathway enrichment revealed biological mechanisms. External validation used GEPIA2.
Results: Cox regression identified 201 survival-associated genes (p<0.05): 149 favorable prognosis (HR<1) and 52 poor prognosis (HR>1). Gene Ontology enrichment revealed 29 immune-associated and 9 extracellular genes, with 5 overlapping candidates. Kaplan-Meier analysis confirmed four genes; EPHA10, CD160, BTN2A2, and KLRK1 as significant protective prognostic markers (p<0.05, HR<1). REACTOME analysis highlighted immune signaling pathways including adaptive immune response, natural killer cell-mediated cytotoxicity, and cell surface interactions. External validation demonstrated differential expression in AML versus normal tissues.
Conclusion: This study identified EPHA10, CD160, BTN2A2, and KLRK1 as novel immune-extracellular prognostic biomarkers in AML. These genes represent promising candidates for liquid biopsy applications and personalized immunotherapy strategies, offering new perspectives for monitoring immune surveillance and overcoming AML immune evasion.
Keywords: Acute myeloid leukemia, Biomarkers, Immune microenvironment, Extracellular genes, Prognosis, TCGA
: Original Article |
Subject:
AI in Medicine
Received: 2025/11/9 | Accepted: 2026/03/7 | Published: 2026/03/31
Received: 2025/11/9 | Accepted: 2026/03/7 | Published: 2026/03/31
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
